Alvotech: Business Overview, Financials & Competitive Analysis
Alvotech scores 7/10 on the AskCyborg Cyborg Score (Strong). Alvotech is a capital-efficient biosimilar pure-play with approved products, strategic partnerships, and a clear path to profitability despite near-term financing needs. Five biosimilars are already approved and marketed in multiple global markets, including biosimilars to Humira (adalimumab), Stelara (ustekinumab), Simponi (golimumab), Eylea (aflibercept) and Prolia/Xgeva (denosumab). Recent leadership transition and significant.
What is Alvotech's industry? Alvotech (alvotech.com) operates in Biotechnology - Biosimilars. AskCyborg classifies Alvotech under Biotechnology - Biosimilars in its company registry.
Alvotech is a global biotech company focused solely on the development and manufacture of biosimilar medicines for patients worldwide. The company's current pipeline contains eight biosimilar candidates aimed at treat...
Cyborg Score thesis
Alvotech is a capital-efficient biosimilar pure-play with approved products, strategic partnerships, and a clear path to...
Read the full analyst-debate transcript →Get the Latest Alvotech Report
Up-to-date AI-powered research, analyst debate audio & saved-company playlists
Get Current Report FreeAlvotech Overview
Pro stress-test →Alvotech is a global biotech company focused solely on the development and manufacture of biosimilar medicines for patients worldwide. The company's current pipeline contains eight biosimilar candidates aimed at treating autoimmune disorders, eye disorders, osteoporosis, and cancer. This focused strategy addresses a critical healthcare need by making expensive biologic medicines more accessible globally.
Strategic Profile
Pro stress-test →Alvotech seeks to be a global leader in the biosimilar space by delivering high quality, cost-effective products and services, enabled by a fully integrated approach and broad in-house capabilities. Alvotech will retain responsibility for development, global clinical activities and manufacturing and will supply finished product to commercial partners under exclusive supply arrangements. The company is actively securing partnerships with major distributors like Sandoz to expand market access while managing capital efficiently.
Competitive Landscape
Pro stress-test →Alvotech competes in the growing biosimilars market against companies like Sandoz (a major distributor partner), Amgen's biosimilar division, and other pure-play biosimilar developers. The company differentiates through vertically integrated manufacturing capabilities and strategic partnerships with established pharmaceutical distributors for market access and regulatory expertise.
Industry Context
Alvotech operates in Biotechnology - Biosimilars.
Key facts
Founded: 2013 · Headquarters: Reykjavik, Iceland · Employees: N/A · Revenue: N/A · Market cap: ~$184.8B ISK (~$1.3B USD equivalent at typical exchange rates)